SK Bioscience has secured the right to independently produce it in Korea by transferring the technology of Novavax vaccine. SK Bioscience announced on the 16th that it has licensed NVX-CoV2373 and signed a contract with the KCDA to supply 40 million doses of vaccine respectively.

SK Bioscience announced on the 16th that it has signed a technology transfer (License In) contract with Novavax for COVID-19 vaccine NVX-CoV2373, and 40 million dose vaccine supply contract with the KCDA.

SK Bioscience signed a CDMO (Contract Development & Manufacturing Orgainzation) contract with Novavax in August last year. Since then, it has completed the transfer of vaccine manufacturing and process technolo